Wilms Henrik, Rosenstiel Philip, Unger Thomas, Deuschl Günther, Lucius Ralph
Clinic of Neurology, Christian-Albrechts-University, Kiel, Germany.
Am J Cardiovasc Drugs. 2005;5(4):245-53. doi: 10.2165/00129784-200505040-00004.
The peptide hormone angiotensin (A)-II, the major effector peptide of the renin-angiotensin system (RAS), is well established to play a pivotal role in the systemic regulation of blood pressure, fluid, and electrolyte homeostasis. Recent biochemical and neurophysiologic studies have documented local intrinsic angiotensin-generating systems in organs and tissues such as the brain, retina, bone marrow, liver, and pancreas. The locally generated angiotensin peptides have multiple and novel actions including stimulating cell growth and anti-proliferative and/or antiapoptotic actions. In the mammalian brain, all components of the RAS are present including angiotensin receptor subtypes 1 (AT(1)) and 2 (AT(2)). A-II exerts most of its well defined physiologic and pathophysiologic actions, including those on the central and peripheral nervous system, through its AT(1) receptor subtype. While the AT(1) receptor is responsible for the classical effects of A-II, it has been found that the AT(2) receptor is linked to totally different signalling mechanisms and this has revealed hitherto unknown functions of A-II. AT(2) receptors are expressed at low density in many healthy adult tissues, but are upregulated in a variety of human diseases. This receptor not only contributes to stroke-related pathologic mechanisms (e.g. hypertension, atherothrombosis, and cardiac hypertrophy) but may also be involved in post-ischemic damage to the brain. It has been reported that the AT(2) receptor regulates several functions of nerve cells, e.g. ionic fluxes, cell differentiation, and neuronal tissue regeneration, and also modulates programmed cell death. In this article, we review the experimental evidence supporting the notion that blockade of brain AT(1) receptors can be beneficial with respect to stroke incidence and outcome. We further delineate how AT(2) receptors could be involved in neuronal regeneration following brain injury such as stroke or CNS trauma. The current review is focussed on some of the new functions arising from the locally formed A-II with particular attention to its emerging neuroprotective role in the brain.
肽激素血管紧张素(A)-II是肾素-血管紧张素系统(RAS)的主要效应肽,在血压、液体和电解质稳态的全身调节中发挥关键作用,这一点已得到充分证实。最近的生化和神经生理学研究记录了在脑、视网膜、骨髓、肝脏和胰腺等器官和组织中存在局部内在的血管紧张素生成系统。局部生成的血管紧张素肽具有多种新作用,包括刺激细胞生长以及抗增殖和/或抗凋亡作用。在哺乳动物脑中,RAS的所有成分都存在,包括血管紧张素受体亚型1(AT(1))和2(AT(2))。A-II通过其AT(1)受体亚型发挥其大部分明确的生理和病理生理作用,包括对中枢和外周神经系统的作用。虽然AT(1)受体负责A-II的经典效应,但已发现AT(2)受体与完全不同的信号传导机制相关联,这揭示了A-II迄今未知的功能。AT(2)受体在许多健康成人组织中低密度表达,但在多种人类疾病中上调。该受体不仅参与与中风相关的病理机制(如高血压、动脉粥样血栓形成和心脏肥大),还可能参与脑缺血后损伤。据报道,AT(2)受体调节神经细胞的多种功能,如离子通量、细胞分化和神经组织再生,还调节程序性细胞死亡。在本文中,我们综述了支持以下观点的实验证据:阻断脑AT(1)受体对中风发生率和预后可能有益。我们进一步阐述了AT(2)受体如何参与脑损伤(如中风或中枢神经系统创伤)后的神经元再生。当前的综述重点关注局部形成的A-II产生的一些新功能,特别关注其在脑中新兴的神经保护作用。